At IgNS Conference, a Focus on New Complement Inhibitors

Several monoclonal antibodies in development could transform care for people with chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and multifocal motor neuropathy who do not respond to other treatments, according to a session at the IgNS 2025 National Conference, in Arlington, Texas.